Abstract
Idiopathic anaphylaxis is a diagnosis of exclusion which falls in the spectrum of mast cell activation disorders. The role of bone marrow biopsy remains controversial, but in the appropriate clinical context, this diagnostic tool may be useful in ruling out a potential systemic mast cell process. There is no definitive treatment for idiopathic anaphylaxis, but omalizumab and rituximab show a promising role in prevention. At this time, data suggesting a role for these two monoclonal antibodies come from case reports but do not prove causation or efficacy of therapy. Clinical trials further investigating efficacy of these options are warranted.
Original language | English (US) |
---|---|
Pages (from-to) | 183-192 |
Number of pages | 10 |
Journal | Current Treatment Options in Allergy |
Volume | 2 |
Issue number | 3 |
DOIs | |
State | Published - Sep 2015 |
Keywords
- Bone marrow biopsy
- Diagnosis
- Idiopathic anaphylaxis
- Mast cell activation
- Omalizumab
- Rituximab
- Treatment
ASJC Scopus subject areas
- Immunology and Allergy
- Medicine (miscellaneous)